Ensysce Biosciences (ENSC) announced the initiation of its live “Ask Me Anything” series on March 4.The event reinforced the Company’s commitment to transparency, accessibility, and open dialogue with its community.The AMA provided Ensysce shareholders and followers with the opportunity to engage directly with Dr. Lynn Kirkpatrick, CEO of Ensysce, covering topics such as Phase 3 execution and timeline visibility, capital discipline and shareholder alignment, as well as strategic priorities and long-term value creation. The event generated numerous distinct questions, arranged under 3 topics reflecting strong engagement and interest from the community.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSC:
- Ensysce Biosciences announces publication on MPAR technology
- Ensysce Biosciences initiates review of strategic alternatives
- Ensysce Biosciences enrolls 50% of subjects in Phase 3 trial of PF614
- Ensysce Biosciences expands global opioid patent portfolio
- Ensysce Biosciences Shareholders Approve Key Corporate Actions